JPRN-UMIN000020185已完成未知
Effects of dapagliflozin on renal function in patients with type 2 diabetes [Diamond study-4] - Effects of dapagliflozin on renal function [Diamond study-4]
Diamond study group0 个研究点目标入组 15 人开始时间: 2015年12月14日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 15
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 70years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •Patients who meet one of the following criteria are ecluded. 1. Patients treated with insulin 2. Patients with unstable angina 3. Patients with severe liver dysfunction (AST >= 100IU/L or ALT >= 100IU/L) 4. Patients with severe renal dysfunction (eGFR < 45 mL/min/1.73m2) 5. Known hypersensitivity to dapagliflozin 6. Patients who are pregnant, possibly pregnant, or nursing 7. A history of traetment with SGLT2 inhibitors including dapagliflozin 8. Patients disqualified by doctor for any reason
研究者
相似试验
招募中
不适用
Effect of Dapagriflozin on renal dysfunction in patients with heart failurechronic heart failureJPRN-UMIN000044902Mitsui Memorial Hospital100
招募中
4 期
Effect of empagliflozin on renal events in non-diabetic chronic kidney disease patientsChronic kidney disease.Chronic kidney disease (CKD)IRCT20211104052965N1Shahid Beheshti University of Medical Sciences458
进行中（未招募）
1 期
The effect of treatment with Dapagliflozin on heart and kidney function after catheter based aortic valve replacement for aortic stenosisPatients with aortic stenosis undergoing trans catheter aortic valve replacement.MedDRA version: 20.0Level: LLTClassification code 10058186Term: Aortic valve stenosis and insufficiencySystem Organ Class: 100000004849EUCTR2021-004271-14-DKAarhus University Hospital, department of Cardiology104
进行中（未招募）
1 期
Effect of Dapagliflozin on myocardial and renal function following aortic valve stenosis interventioAortic stenosisCTIS2024-514868-11-00Aarhus Universitetshospital106
进行中（未招募）
1 期
Effect of the dapagliflozin drug on the glomerular hyperfiltration in nondiabeticobese patients.This study aims to demonstrate the hypothesis that treatment with dapagliflozin 10mg lowers in at least 10-20% of measured glomerular filtration rate (mGFR) in non-diabetic obese patients with glomerular hyperfiltration.EUCTR2019-002262-12-ESHospital Universitari Germans Trias i Pujol60